SCHEMBL5012209

SCHEMBL5012209

Cc1ccc(C(=O)Nc2cc(C(=O)NCc3ccccc3)n[nH]2)c(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
EGFR P00533 1/20 0.45
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
RET P07949 1/20 0.43
PPARG P37231 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HCRTR1 O43613 1/20 0.43
MMP13 P45452 1/20 0.43
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5012093 0.89 ADORA2A (0.47) CYP1A2CYP2D6CYP2C19ADORA2AEGFR
SCHEMBL5009734 0.84 CYP1A2 (0.47) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL5009903 0.83 SMN1; SMN2 (0.50) CYP1A2CYP2D6CYP2C19ADORA2AALDH1A1
SCHEMBL5013486 0.83 PPARG (0.54) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD
SCHEMBL5012232 0.82 JAK2 (0.48) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL5008281 0.82 SMN1; SMN2 (0.55) CYP1A2CYP2D6CYP2C19ALDH1A1KDM4E
SCHEMBL5010776 0.82 GAA (0.56) CYP1A2CYP2C19ALDH1A1HPGDSMN1; SMN2
SCHEMBL5010346 0.80 PPARG (0.48) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD
SCHEMBL5010453 0.80 NSD2 (0.46) CYP1A2CYP2D6CYP2C19ADORA2AALDH1A1
SCHEMBL5013503 0.80 PPARG (0.50) CYP1A2CYP2C19ALDH1A1SMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL CYP1A2 683/4885CYP2D6 136/4885CYP2C19 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.